saic-logo

Science Applications International Corp.'s $473 million acquisition of maxIT Healthcare Holdings Inc. will more than double the company's commercial health care business and make good on a two-year strategy to expand SAIC's presence in that market, company executives told Washington Business Journal Wednesday.

The deal, announced Tuesday evening and expected to close in August, will create a health care business worth just north of $850 million and add about 1,300 employees to the SAIC workforce. Westfield, Ind.-based maxIT will function as a wholly owned subsidiary, with no layoffs planned and additional hires anticipated.

humana-logo

Health benefits and health care company Humana Inc. has agreed to sponsor Blueprint Health, a New York City-based business accelerator for entrepreneurs in the health care and well-being industry.

According to a news release, Louisville-based Humana will be the exclusive health insurance platinum sponsor of the summer 2012 Blueprint Health Accelerator. Terms of the sponsorship were not disclosed.

Johns Hopkins University

Johns Hopkins University and 11 other universities are teaming up with a for-profit company founded by two Stanford University computer science professors to offer free Internet courses worldwide, the Wall Street Journal reported Tuesday.

The schools joined four others already working with Coursera, a for-profit education technology company, which will offer over 100 online courses beginning this fall, the WSJ reported.

NIH Careers

The NIH is the premier biomedical research center for the world. Its 27 Institutes and Centers employ approximately 18,000 employees doing a vast array of jobs, all supporting efforts for a healthy nation. For information on the NIH mission, goals, and Institutes and Centers, visit NIH Overview.

As part of the National Institutes of Health (NIH) mission to support biomedical research and reduce the burden of illness worldwide, the NIH Roadmap Initiative outlines the need to position the NIH to address the evolving public health challenges of the 21st Century and to enhance public-private partnerships. To support this mission, the NIH Office of Technology Transfer (OTT) is working to address global health challenges by facilitating the transfer of technologies to people around the world.

human-genome-sciences

Rockville-based Human Genome Sciences Inc., which rejected a $13-per-share takeover offer from GlaxoSmithKline PLC as too low, has accepted a $14.25 per share offer from its lupus drug development partner. The handshake brings to a close a monthslong, sometimes tense struggle for control of the company.

Glaxo announced Monday that Human Genome Sciences (NASDAQ: HGSI) had agreed to its offer to acquire the company in a $3.6 billion squirt transaction that values Human Genome at $3 billion net of cash and debt.

Human Genome

U.K. drug maker GlaxoSmithKline said Monday it had secured its takeover of Rockville-based Human Genome Sciences after agreeing to pay a higher price for the U.S. biotechnology company.

In a joint announcement by the two companies, GSK said it would pay $14.25 per share for Human Genome Sciences, up from its previous offer of $13 per share. The offer values Human Genome Sciences at $3.6 billion.

human-genome-lab

GlaxoSmithKline of Britain is near a deal to buy the biopharmaceutical company Human Genome Sciences on friendly terms for about $2.8 billion, potentially ending a long hostile takeover campaign, a person briefed on the matter said on Sunday.

Under the new terms of the deal, GlaxoSmithKline would pay about $14 a share in cash, this person said.

jhutt

The Johns Hopkins Technology Transfer Office (JHTT) is the University’s intellectual property administration center, serving Johns Hopkins researchers and inventors as a licensing, patent, and technology commercialization office and acting as an active liaison to parties interested in leveraging JHU research or materials for academic or corporate endeavors. SNNLive spoke with Wesley Blakeslee, Executive Director of Johns Hopkins Technology Transfer Office at the BioMaryland booth at the BIO International Convention 2012 in Boston, MA.

jhu-logo

Johns Hopkins University is creating a new center to help public health agencies and accountable provider or payer groups better take advantage of health IT technologies.

The Johns Hopkins Center for Population Health IT, or CPHIT, is intended to broaden the focus of health IT systems including electronic health records and e-health beyond clinicians treating individual patients, says Jonathan Weiner, director of the new center. The idea is to "harness these health IT systems to create solutions for the many population health issues facing our nation," he says in a July 11 announcement.

human-genome-sciences

As more drug manufacturers fight for a share of the market, those with biotech sales jobs understand that their companies' success lies in its ability to develop innovative new products. Now, Maryland-based Human Genome Sciences has announced its breakthrough treatment for inhalational anthrax is one step closer to commercialization.

The company said the Food and Drug Administration (FDA) has acknowledged receipt of its resubmission of the Biologics License Application (BLA) for raxibacumab, a human monoclonal antibody that differs from other treatments because it targets anthrax toxins after they are released by bacteria into the blood and tissues of the body.

venture-debt

Cash-burning R&D-stage biotechs have big appetites for cash, which is typically addressed with an equity-based diet.  It’s also supported through corporate partnerships and other less dilutive means such as grants and foundation funding.  But another important and often under-appreciated source of capital are the debt markets – taking a loan out to provide working capital for further R&D.

One might ask why and how a company that won’t have profits for a decade can raise any money through the issuance of debt, but it happens frequently, and the “venture lending” business is actually very robust.  Players like Silicon Valley Bank (SVB), Oxford Finance, Hercules Technology Growth Capital, and Horizon Technology Finance (and many others) are all very active supporters of emerging life science companies.